 Crosslinking, CXL, is a minimally invasive procedure used to treat keratoconus and secondary ectasia. It has been shown to be effective in reducing the progression of these conditions, however, there are potential risks associated with the procedure. These include the risk of infection from the removal of the epithelium, the formation of corneal haze, permanent scar tissue, endothelial damage, sterile infiltrates, and herpes reactivation. Additionally, there can be direct or indirect complications related to the use of a therapeutic soft contact lens, poor patient hygiene, and untreated comorbidities. Despite these risks, CXL is generally considered safe and effective when performed by experienced surgeons. This article was authored by Shikodawan, Kavita IO, and Sundaram Natrogen.